Approval Granted for SOLVD Health’s New York State Laboratory
SOLVD Health, a patient intelligence company specializing in advanced precision solutions to improve health outcomes, has received approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for its San Diego-based laboratory. This approval allows SOLVD Health to offer AvertD® to patients in New York, providing healthcare providers and patients with vital insights to reduce the risk of opioid use disorder (OUD).
The approval from New York State Department of Health’s Clinical Laboratory Evaluation Program is a significant milestone for SOLVD Health, as it enables the company to expand its reach and offer its FDA-approved AvertD® genetic test to a broader patient base in New York. AvertD® is designed to assess an individual’s genetic risk for OUD, offering healthcare providers valuable insights to personalize pain management strategies and reduce the risk of opioid misuse.
New York State’s Department of Health is well-known for its stringent standards in clinical laboratory testing, ensuring that only laboratories that meet the highest benchmarks for accuracy, reliability, and patient safety receive approval. SOLVD Health’s successful approval demonstrates its commitment to maintaining high-quality, clinically validated genetic testing. This ensures that healthcare providers can make informed decisions when it comes to pain management for patients at risk of developing opioid use disorder.
“This approval marks a pivotal step in our mission to expand access to genetic testing that can help address the opioid crisis,” said Dr. Keri Donaldson, founder and CEO of SOLVD Health. “With this approval, more healthcare providers and patients in New York can benefit from AvertD®, which will help guide decisions about pain management and potentially prevent adverse outcomes.”
The opioid epidemic continues to be one of the most significant public health challenges. Healthcare providers are increasingly seeking tools that allow them to understand the genetic factors influencing how patients respond to opioids. AvertD® provides clinically validated insights into a patient’s genetic susceptibility to OUD, allowing healthcare professionals to assess risk before prescribing opioids. By incorporating genetic data into pain management plans, providers can reduce the likelihood of opioid addiction, misuse, or overdose.
AvertD® represents a breakthrough in precision medicine, offering a way to personalize pain management for individuals at risk of OUD. The test evaluates genetic markers that impact opioid metabolism, a patient’s response to pain medications, and the potential for developing OUD. With this information, healthcare providers can make more informed decisions, ensuring that pain management plans are tailored to each patient’s unique genetic makeup.
This approval from New York State is a key moment for SOLVD Health, as it advances the company’s mission to address the opioid crisis by offering genetic testing to better understand individual patients’ risk factors. The approval will help healthcare providers make more personalized decisions regarding opioid prescriptions and could play a critical role in reducing the number of new opioid addiction cases, ultimately improving long-term patient outcomes.
SOLVD Health’s approach to healthcare is rooted in providing actionable insights based on genetic data. The company believes that by making this data accessible to both individuals and healthcare providers, they can significantly improve decision-making and overall health outcomes. By offering solutions like AvertD®, SOLVD Health is advancing the field of personalized medicine, working toward a future where precision healthcare becomes the standard of care.
In conclusion, the approval of SOLVD Health’s AvertD® by the New York State Department of Health is a significant development for both the company and healthcare providers in the state. This approval not only expands access to valuable genetic testing for opioid use disorder but also empowers patients and healthcare providers with the insights needed to make more informed decisions about pain management. SOLVD Health’s ongoing work in precision medicine holds great promise in the fight against the opioid epidemic.
About SOLVD Health
SOLVD Health is a privately held company dedicated to preventing disease by making contextual health information accessible to everyone. Through the development of cutting-edge, insights-based health tools, SOLVD Health empowers individuals and their healthcare providers to make better decisions about their health. The company achieves this by translating complex biological data into actionable insights that guide more informed health decisions. SOLVD Health is committed to improving health outcomes by focusing on precision medicine and delivering tools that help individuals lead healthier lives.
Please find the related post
